NCT01196871View on ClinicalTrials.gov

Drug-Drug Interaction Study Between AT1001 (Migalastat Hydrochloride) and Agalsidase in Participants With Fabry Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

February 2, 2011

Primary Completion Date

October 9, 2012

Study Completion Date

October 9, 2012

Conditions
Fabry Disease
Interventions
DRUG

Migalastat HCl

Oral capsules, single dose

BIOLOGICAL

Agalsidase Beta

IV infusion, single dose

BIOLOGICAL

Agalsidase Alfa

IV infusion, single dose

Trial Locations (10)

22152

Springfield

30033

Decatur

35294

Birmingham

52242

Iowa City

66160

Kansas City

Unknown

Nedlands

Parkville

Edegem

Montreal

Amsterdam

Sponsors
All Listed Sponsors
lead

Amicus Therapeutics

INDUSTRY